Skip to main content

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

EXPLORE ASTHMA

 

DUPIXENT is indicated as an add-on maintenance
treatment of adult patients with inadequately
controlled chronic obstructive pulmonary disease
(COPD) and an eosinophilic phenotype.

Limitations of Use: DUPIXENT is not indicated
for the relief of acute bronchospasm.

EXPLORE COPD

MEET THE ASTHMA PATIENTS REVIEW ASTHMA DATA EXPLORE ASTHMA MOA

DISCOVER THE
DUPIXENT DIFFERENCE

IN ASTHMA AND IN COPD

The only biologic that directly inhibits
IL-4 and IL-13 signaling—two of the key drivers of type 2 inflammation1,*

*The mechanism of dupilumab action
has not been definitively established.

Not actual DUPIXENT patients.

MEET THE COPD PATIENTS REVIEW COPD DATA EXPLORE COPD MOA

See the impact of dupixent

#1 biologic

prescribed by pulmonologists
and allergists2,3,a,b

>1 million

patients on therapy across
approved indications worldwide4,c

a#1 prescribed biologic by pulmonologists includes the aggregate number of new to brand across all indications. Source: Data on file, Sanofi US. New to Brand Weekly Audit; data through February 2026.2

b#1 prescribed biologic by allergists includes the aggregate number of new to brand across indications. Source: Data on file, Sanofi US. New to Brand Monthly Audit; data through December 2025.3

cThe worldwide patient number is largely composed of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ~14% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through December 2025.4

AD, atopic dermatitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis; PN, prurigo nodularis.